In vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis

doi:10.3748/wjg.v23.i46.8152

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8452)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-2) series.

Item

Count

PDF

675

WORD

241

HTML

4701

Figures (1-7)

337

Tables (1-2)

161

Sum=6115

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

968

Download

1369

Sum=2337

Dec 14, 2017 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (46)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Dec 14, 2017; 23(46): 8152-8168
Published online Dec 14, 2017. doi: 10.3748/wjg.v23.i46.8152

Table 1 Impact of mesenchymal stem cells on liver function indexes in each group (n = 10, mean ± SD)

Group		ALT(U/L)	AST(U/L)	ALB(g/L)	TBIL (µmol/L)	DBIL (µmol/L)
Liver fibrosis groups	Saline/CCl₄ 1 wk	141.00 ± 16.33	150.76 ± 15.13	29.99 ± 1.53	0.97 ± 0.15	0.70 ± 0.02
	MSCs/CCl₄ 1 wk	130.32 ± 15.35	142.32 ± 14.24	32.17 ± 2.25	0.93 ± 0.08	0.60 ± 0.04
	Saline/CCl₄ 2 wk	152.35 ± 14.56	172.22 ± 19.34	24.54 ± 1.21	1.51 ± 0.21	0.90 ± 0.07
	MSCs/CCl₄ 2 wk	132.88 ± 13.23^a	146.23 ± 13.23a	26.60 ± 2.34	1.33 ± 0.25	0.70 ± 0.05
	Saline/CCl₄ 4 wk	239.24 ± 26.32	262.34 ± 28.12	28.12 ± 2.13	2.10 ± 0.23	1.10 ± 0.17
	MSCs/CCl₄ 4 wk	192.32 ± 21.24^b	204.52 ± 23.24^b	21.12 ± 1.94^b	1.57 ± 0.15^b	0.50 ± 0.03^b
Liver cirrhosis groups	Saline/CCl₄ 2 wk	334.36 ± 37.48	375.24 ± 41.26	26.55 ± 1.51	2.27 ± 0.15	1.32 ± 0.12
	MSCs/CCl₄ 2 wk	204.31 ± 22.52^c	289.13 ± 32.22^c	19.62 ± 1.54	1.90 ± 0.14^c	0.80 ± 0.09^c
	Saline/CCl₄ 4 wk	353.35 ± 38.76	406.24 ± 44.31	22.69 ± 2.72	3.34 ± 0.76	2.07 ± 0.15
	MSCs/CCl₄ 4 wk	214.11 ± 23.24^d	292.24 ± 32.32^d	20.36 ± 1.53^d	2.06 ± 0.14^d	1.10 ± 0.13^d
	Saline/CCl₄ 8 wk	391.22 ± 43.57	418.63 ± 45.71	19.31 ± 1.52	4.82 ± 0.52	3.74 ± 0.25
	MSCs/CCl₄ 8 wk	247.31 ± 27.36^e	307.22 ± 34.36^e	23.70 ± 7.72^e	3.32 ± 0.31^e	2.13 ± 0.15^e

^aP < 0.05 vs Saline/CCl₄ 2 wk,

^bP < 0.05 vs Saline/CCl₄ 4 wk (in the liver fibrosis groups);

^cP < 0.05 vs Saline/CCl₄ 2 wk,

^dP < 0.01 vs Saline/CCl₄ 4 wk, and

^eP < 0.01 vs Saline/CCl₄ 8 wk (in the liver cirrhosis groups). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TBIL: Total bilirubin; DBIL: Direct bilirubin.

Table 2 Inflammation scores in each group (n = 10, mean ± SD)

	Liver fibrosis groups			Liver cirrhosis groups
	1 wk	2 wk	4 wk	2 wk	4 wk	8 wk
Saline/CCl₄	1.63 ± 0.05	1.95 ± 0.06	2.67 ± 0.08	3.09 ± 0.07	3.61 ± 0.09	4.12 ± 0.11
MSCs/CCl₄	1.25 ± 0.04	1.45 ± 0.05^a	1.75 ± 0.07^b	2.15 ± 0.06^c	2.28 ± 0.07^d	3.06 ± 0.08^d

^aP < 0.05 vs Saline/CCl₄ 2 wk,

^bP < 0.05 vs Saline/CCl₄ 4 wk (in the liver fibrosis groups);

^cP < 0.05 vs Saline/CCl₄ 2 wk,

^dP < 0.01 vs Saline/CCl₄ 4 wk, (in the liver cirrhosis groups).

Citation: Zhang GZ, Sun HC, Zheng LB, Guo JB, Zhang XL. In vivo hepatic differentiation potential of human umbilical cord-derived mesenchymal stem cells: Therapeutic effect on liver fibrosis/cirrhosis. World J Gastroenterol 2017; 23(46): 8152-8168
URL: https://www.wjgnet.com/1007-9327/full/v23/i46/8152.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i46.8152